ATE268377T1 - Ex-vivo unter oxidativen stress behandelte cll- zellen zur behandlung chronischer lymphozytärer läukemie (cll) - Google Patents

Ex-vivo unter oxidativen stress behandelte cll- zellen zur behandlung chronischer lymphozytärer läukemie (cll)

Info

Publication number: ATE268377T1
Authority: AT; Austria
Prior art keywords: cll; lymphocytic leukemia; chronic lymphocytic; treatment; oxidative stress
Prior art date: 2000-10-25

Application number

AT01981999T

Other languages

English (en)

Inventor

David Elliott Spaner

Original Assignee

Vasogen Ireland Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-25

Filing date

2001-10-25

Publication date

2004-06-15

2001-10-25 Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd

2004-06-15 Application granted granted Critical

2004-06-15 Publication of ATE268377T1 publication Critical patent/ATE268377T1/de

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0023—Agression treatment or altering
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Wood Science & Technology (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Microbiology (AREA)
Virology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Hematology (AREA)
Immunology (AREA)
Developmental Biology & Embryology (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT01981999T 2000-10-25 2001-10-25 Ex-vivo unter oxidativen stress behandelte cll- zellen zur behandlung chronischer lymphozytärer läukemie (cll) ATE268377T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CA 2324199 CA2324199A1 (en)	2000-10-25	2000-10-25	Chronic lymphocytic leukemia treatment
PCT/CA2001/001497 WO2002034888A1 (en)	2000-10-25	2001-10-25	Ex vivo oxidatively stressed cll cells in chronic lymphocytic leukemia (cll) treatment

Publications (1)

Publication Number	Publication Date
ATE268377T1 true ATE268377T1 (de)	2004-06-15

Family

ID=4167457

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01981999T ATE268377T1 (de)	2000-10-25	2001-10-25	Ex-vivo unter oxidativen stress behandelte cll- zellen zur behandlung chronischer lymphozytärer läukemie (cll)

Country Status (8)

Country	Link
US (1)	US6733748B2 (de)
EP (1)	EP1330514B1 (de)
AT (1)	ATE268377T1 (de)
AU (1)	AU2002213700A1 (de)
CA (1)	CA2324199A1 (de)
DE (1)	DE60103658D1 (de)
NZ (1)	NZ525275A (de)
WO (1)	WO2002034888A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050063995A1 (en) *	2001-10-25	2005-03-24	Spaner David E	Compositions and methods for selected tumour treatment
CA2377442A1 (en) *	2002-03-20	2003-09-20	Thomas Ichim	Increasing tumor oxygen content by administration of stressed cells
AU2003266086A1 (en) *	2002-09-16	2004-04-30	Vasogen Ireland Limited	Chronic lymphocytic leukemia combination treatment (treated cll cells and cytokine)
US20060189543A1 (en) *	2005-02-23	2006-08-24	Rosenbloom Richard A	Compositions and methods for the treatment of leukemia
WO2010033771A2 (en) *	2008-09-19	2010-03-25	Trustees Of The University Of Pennsylvania	Modulators of hsp70/dnak function and methods of use thereof
US9943607B2 (en)	2011-05-09	2018-04-17	Biothera, Inc.	Beta-glucan compounds, compositions, and methods
US10010560B2 (en)	2014-02-26	2018-07-03	The Trustees Of The University Of Pennsylvania	Small molecule HSP70 inhibitors
US20210000936A1 (en) *	2018-03-21	2021-01-07	Colorado State University Research Foundation	Cancer vaccine compositions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5980954A (en) *	1992-02-07	1999-11-09	Vasogen Ireland Limited	Treatment of autoimmune diseases
US6649364B1 (en)	1995-06-07	2003-11-18	The Regents Of The University Of California	Anti-apoptotic compositions and methods using same
EP1028754B1 (de)	1997-11-12	2008-08-27	The Trustees Of The University Of Pennsylvania	Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
CA2244554A1 (en)	1998-07-30	2000-01-30	Vasogen Inc.	Inhibition of graft versus host disease
WO2000041705A1 (en)	1999-01-12	2000-07-20	Vasogen Ireland Limited	Pre-conditioning against cell death
CA2297448A1 (en)	2000-01-28	2001-07-28	Vasogen Inc.	Improved inhibition of graft versus host disease

2000
- 2000-10-25 CA CA 2324199 patent/CA2324199A1/en not_active Abandoned
2001
- 2001-10-25 NZ NZ525275A patent/NZ525275A/en unknown
- 2001-10-25 AT AT01981999T patent/ATE268377T1/de not_active IP Right Cessation
- 2001-10-25 WO PCT/CA2001/001497 patent/WO2002034888A1/en active IP Right Grant
- 2001-10-25 EP EP01981999A patent/EP1330514B1/de not_active Expired - Lifetime
- 2001-10-25 AU AU2002213700A patent/AU2002213700A1/en not_active Abandoned
- 2001-10-25 DE DE60103658T patent/DE60103658D1/de not_active Expired - Lifetime
- 2001-10-25 US US09/999,850 patent/US6733748B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1330514A1 (de)	2003-07-30
US6733748B2 (en)	2004-05-11
EP1330514B1 (de)	2004-06-02
DE60103658D1 (de)	2004-07-08
NZ525275A (en)	2004-08-27
CA2324199A1 (en)	2002-04-25
US20020090358A1 (en)	2002-07-11
WO2002034888A1 (en)	2002-05-02
AU2002213700A1 (en)	2002-05-06

Similar Documents

Publication	Publication Date	Title
ATE106740T1 (de)	1994-06-15	Herstellung von t-zellen und t-zellmembranen, verwendbar zur verhütung und behandlung von autoimmunkrankheiten.
ATE462427T1 (de)	2010-04-15	Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
US20100028849A1 (en)	2010-02-04	Novel process for devitalized/acellular tissue for transplantation
NO20075065L (no)	1999-02-25	Anvendelse av isoflavonforbindelser til a behandle hjertesykdom
ES8505405A1 (es)	1985-05-16	Un procedimiento para producir un activador de plasminogeno purificado.
TR199901172T2 (xx)	1999-08-23	Yeni ikame edilmi� pirazol t�revleri.
ATE281839T1 (de)	2004-11-15	Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut
EA200400482A1 (ru)	2004-12-30	Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
ECSP055609A (es)	2005-04-18	"Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
NO20013004D0 (no)	2001-06-15	Anvendelse av biokjemiske substanser i en sammensetning for forhindringen og behandlingen av helsetilstander forårsaket avkonstriksjon av glattmuskelceller i organer i det menneskeligelegemet
EA200700074A1 (ru)	2007-08-31	Способ повышения скорости заживления повреждения ( варианты ), устройство доставки перекиси водорода и композиция для лечения повреждений у млекопитающих
EE9700225A (et)	1998-02-16	Meetod diabetes mellituse raviks, kasutades KKF
EP1759715A4 (de)	2007-05-30	Sterilisationssystem
ATE97316T1 (de)	1993-12-15	Kosmetisches mittel und zusammensetzung zur behandlung der haut.
ATE299854T1 (de)	2005-08-15	Chinonverbindungen zur behandlung von krankheiten
DE60225590D1 (de)	2008-04-24	C-kithemmer zur behandlung von bakteriellen infektionen
ATE268377T1 (de)	2004-06-15	Ex-vivo unter oxidativen stress behandelte cll- zellen zur behandlung chronischer lymphozytärer läukemie (cll)
ATE421329T1 (de)	2009-02-15	Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
Néri et al.	2017	Ozone therapy influence in the tissue repair process: a literature review
ATE473728T1 (de)	2010-07-15	Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
DE69829202D1 (de)	2005-04-07	Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DE69725882D1 (de)	2003-12-04	Adenovirus e4 proteine für induktion von zelltod
AU721530B2 (en)	2000-07-06	Endothelial lining effects and treatment of vasospastic disorders
DE602004030661D1 (de)	2011-02-03	Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
BR9608147A (pt)	1999-12-07	Método para descontaminação microbiana de plaquetas sanguìneas.

Legal Events

Date	Code	Title	Description
2004-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties